Rumiko Shimazawa, Masayuki Ikeda. Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech). Journal of Pharmaceutical Policy and Practice. 2021. 14. 1. 46-46
Rumiko Shimazawa, Masayuki Ikeda. Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: A tripartite comparison. British Journal of Clinical Pharmacology. 2021. 87. 10. 3938-3948
Rumiko Shimazawa, Masayuki Ikeda. Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan. Expert review of molecular diagnostics. 2020. 20. 6. 601-610
朝倉 崇徳, 池田 正行, 中村 朗, 小寺 聡. ESBL産生EnterobacteriaceaeのUTIsに対する非カルバペネム系抗菌薬を用いた経験的治療の効果(Efficacy of empirical therapy with non-carbapenems for UTIs with ESBL-producing Enterobacteriaceae). 日本内科学会雑誌. 2015. 104. Suppl. 279-279
Draft Guidance for Industry and Food and Drug Administration Staff : In Vitro Companion Diagnostic Devices Draft Guidance. 2012. 43. 6. 514-519
Reflection Paper on Methodological Issues Associated with Pharmacogenomic Biomarkers in Relation to Clinical Development and Patient Selection : Draft (2). 2012. 43. 12. 1097-1105
EMAヒト用医薬品委員会, 嶋澤 るみ子, 池田 正行. Reflection Paper on Methodological Issues Associated with Pharmacogenomic Biomarkers in Relation to Clinical Development and Patient Selection : Draft (1). 医薬品医療機器レギュラトリーサイエンス. 2012. 43. 11. 1010-1016
Companion and Complementary Diagnostics From Biomarker Discovery to Clinical Implementation
Elsevier 2019
Companion Diagnostics (CDx) in Precision Medicine
Jenny Stanford Publishing 2019
Professional career (1)：
医学博士 (東京医科歯科大学)
Association Membership(s) (4)：
JAPAN PRIMARY CARE ASSOCIATION
, JAPANESE SOCIETY OF NEUROLOGY
, THE JAPANESE SOCIETY OF INTERNAL MEDICINE
, THE JAPANESE ASSOCIATION OF PHARMACEUTICAL MEDICINE
